This high-resolution Cellvizio^Ž GI mosaic image shows in vivo colon tissue at the cellular level exhibiting chronic inflammation, visible lymphatic vessels, and general scarring of surrounding tissue. The differential diagnosis is an indication of Crohn's disease. This link shows the real time video of this unique image obtained with the Cellvizio GI system.

Image courtesy of Dr. Evelien Dekker, Academic Medical Center, Amsterdam

At the upcoming DDW, a number of presentations will highlight Cellvizio GI technology.

Dr. Anna Buchner of the Mayo Clinic, in Jacksonville, Florida, will highlight Cellvizio GI technology in advancing diagnosis of colorectal neoplasia in vivo. Her important work will be presented in the Late Breaking Abstract Oral Session on Tuesday,
5/20, 2:15 - 3:45pm, Room 29:

"High Resolution Confocal Endomicroscopy Probe System for In Vivo Diagnosis of Colorectal Neoplasia"

4 posters presentations are also of note, available for review on the days shown below from 8am-5pm, in the Sails Pavilion. Authors are available poster-side from noon to 2pm.

Sunday 5/18 - S1161:

"Detection of Cholangiocarcinoma in-Vivo Using Miniprobe-Based Confocal Microscopy," A Meining, Technical University of Munich."

Sunday 5/18 - S1169:

"Miniprobe Based Confocal Fluorescence Microscopy Is Feasible for Recognition of Histological Features In-Vivo for the Prediction of Final istopathology in Patients with Longstanding Ulcerative Colitis," FJ van den Broek, Academic Medical Center, Amsterdam

Sunday 5/18 - S1392:

"Accuracy of Miniprobe Confocal Laser Microscopy for Detection of Barrett Neoplasia,"
Histopathology Pohl, Veterans Administration Medical Center, White River Junction, Vermont

Monday 5/19 - M1316:

"Confocal Laser Microscopy Guided Endoscopic Mucosal Resection in Barrett's Esophagus with High Grade Dysplasia,"
RJ Badreddine, Mayo Clinic; Rochester, Minnesota

Colon Cancer Detection Earlier, Faster,

Stanford University School of Medicine, California

The combination of targeted peptide probes with Cellvizio^Ž GI imaging provides a powerful tool with the potential to improve the early detection of cancer. This new clinical study reports colon cells probed with peptides in vivo and imaged with Cellvizio GI can detect early stage cancerous polyps in real time. Results were well correlated with biopsies in the initial trial of 15 patients. Christopher Contag, PhD, anticipates that the technique may be expanded to assess signs of neoplasm earlier, evaluate chemotherapeutic effects and refine cancer treatments.

Full report available at www.nature.com/naturemedicine

Nature Medicine 2008 Apr;14(4):454-8.

Cellvizio^Ž GI ERCP Mini-Probe Debuts

At DDW, a specially designed mini-probe debuts that enables the Cellvizio GI system to be used with endoscopic retrograde cholangiopancreatography (ERCP). This new mini-probe allows imaging of pancreatic and biliary structures, previously difficult to visualize. This new mini-probe fits standard duodeno-scopes, cholangioscopes and ERCP catheters, so workflow does not change. The new mini-probe should enable clearer differentiation of structures and improve diagnosis of neoplasia of the pancreatic and biliary ducts.

Dr. Alexander Meining, Technical University of Munich

Q. What did you feel when you were first introduced to
Cellvizio^® GI?
A. I was amazed, because you see moving, living cells in vivo during an ongoing endoscopy. I had the impression that I was detecting an absolutely new world of endoscopic imaging. It's very easy to use, and you get good images rather fast.

Q. Can Cellvizio be used with other enhanced endoscopic techniques, such as narrow band imaging?
A. Cellvizio has the advantage that we may use it with any kind of endoscope, and other enhanced imaging technologies, such as narrow band imaging and autofluorescence.

Mauna Kea Technologies, based in Paris, is increasing its commercialization efforts in the U.S. In early 2008, Chris Tihansky was named President of its U.S. subsidiary, Cellvizio Inc., based in the Philadelphia area. He can be reached at +1 (888) 590-1798 or by email: tihansky@maunakeatech.com

Chris has 20 years of experience in emerging medical technology and healthcare financial services. He most recently served as President and CEO of Surgical Services Inc., a division of Teleflex Inc. Chris received a Bachelor of Science Degree in Mechanical Engineering from Lehigh University; a Master of Science Degree in Biomedical Engineering from Drexel University; and an MBA from the University of San Diego.

Chris Tihansky MS, MBA, President, Cellvizio Inc.